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Less Is More.More or Less?*Jamie Layland, MBCHB, PHD,y Colin Berry, MBCHB, PHDzA fter its introduction to the clinical arenamore than 20 years ago (1,2), fractional ﬂowreserve (FFR) has become an increasingly
utilized tool for optimizing revascularization deci-
sions in patients with coronary artery disease (3–6).
However, despite the evidence base from large ran-
domized trials, registries, and clinical guideline rec-
ommendations (7), FFR is not universally adopted.
Some of the reasons for this discord relate to cost,
difﬁculty interpreting FFR in certain clinical situa-
tions, as well as issues relating to the drugs required
for the procedure. Such issues have prompted other
researchers to look to ‘drug free’ indexes to assess
stenosis severity (8).
The use of FFR is predicated on the induction of
maximal hyperemia such that measures of pressure
become proportional to coronary blood ﬂow (9).
Adenosine is one of the most commonly used drugs
to achieve hyperemia in the catheter laboratory.
Both intracoronary (IC) and intravenous (IV) methods
of delivering adenosine are capable of producing
hyperemia, although the IV method is regarded as the
current gold standard (10). However, although the IV
route poses several practical advantages, such as the
potential to perform a pressure wire pullback in sit-
uations of tandem lesions or diffusely diseased cor-
onary arteries, IV adenosine administration can be*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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paper to disclose.more time-consuming and costly due to the larger
amount of adenosine required for FFR assessment.
Thus, the IC route is potentially a more attractive
option in the assessment of FFR.
Earlier studies had suggested a maximal IC dose of
adenosine of 16 mg for the left coronary artery and 12
mg for the right coronary artery (11) with increasing
doses of 2 orders of magnitude to ensure maximal
vasodilation (12). These protocols were challenged by
animal data suggesting that higher doses of adeno-
sine may be needed to achieve maximal hyperemia
(13) and clinical studies that suggested that standard
adenosine dosing failed to achieve maximal hyper-
emia compared with papaverine and IV adenosine
(10,14). Current recommendations for IC adenosine
dosing are 40 mg in the right coronary artery and 60 mg
in the left coronary artery, increasing the doses
incrementally by 30 mg to a maximum of 150 mg (15).
A key and contentious question remaining is
whether the IC route is as efﬁcacious at producing
maximal hyperemia compared with the IV route. In
general, IC adenosine has been associated with lower
efﬁcacy compared with IV adenosine (14,16). How-
ever, most studies performed to date have used
differing methodologies and adenosine doses. Most
recently, Leone et al. (17) examined the response of
IC adenosine compared with IV adenosine using
increasing adenosine doses. Although there was a
reduction in FFR at higher IC doses, the absolute
difference (and clinical signiﬁcance) was negligible
(60-mg mean FFR, 0.88 vs. 300-mg mean FFR, 0.87).
Importantly, as the IC dose increased, the incidence
of atrioventricular (AV) block increased (nearly 25% of
patients). Thus, it appears from studies to date that
although the IV route of administration has a greater
efﬁcacy for achieving maximal hyperemia compared
with the conventional IC dosing, how important this
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1432is in the clinical setting is debatable. Moreover, the
use of IV adenosine is associated with more systemic
side effects than the intracoronary route such as
ﬂushing, chest pain and dyspnea and these unwanted
effects are some of the reasons why clinicians do not
want to use adenosine (18). However, due to con-
ﬂicting evidence, clinicians are often reluctant to use
IC adenosine due to a perceived lack of conﬁdence in
its ability to produce maximal hyperemia.SEE PAGE 1422In this issue of JACC: Cardiovascular Interventions,
Adjedj et al. (19) assess the use of intracoronary
adenosine in a small-dose response study (19). The
authors should be congratulated for a well-performed
study adding valuable and reassuring data to the use
of IC adenosine for the attainment of hyperemia.
Using increasing doses of IC adenosine (up to 500 mg),
the group measured pressure and ﬂow velocity in
patients with near-normal coronary arteries. Using a
dose-response and physiological model–based
approach, an optimal cutoff dose for IC adenosine
was attained, balancing the incremental effect on
hyperemia with the risk of AV block. The groupsurmised that the optimal dose for the right coronary
artery was 100 mg and 200 mg for the left coronary
artery to provide an FFR within 0.01 of the value at
100% hyperemia. Of interest, only doses >100 mg
were associated with AV block.
Although these results are informative, the study is
limited by the small sample size and the use of a
normalized ﬂow velocity in relation to the highest
dose of adenosine (500 mg) as the reference standard.
An alternative method would have been to also use
IV adenosine and use this as a reference standard.
Despite these minor shortcomings, the study adds to
the weight of evidence that IC adenosine is adequate
for achieving a sufﬁcient hyperemic response in most
patients. Furthermore, due to its ease of use and lack
of side effects for patients, it may be the preferred
route of delivery when more complex assessments
relating to diffuse disease, tandem stenosis, and
microvascular function are not required.
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